A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects Aged 10-17 Years of Age With Iron Deficiency
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Ferric maltol (Primary)
- Indications Iron deficiency anaemia
- Focus Pharmacokinetics
- Sponsors Shield Therapeutics
- 30 Oct 2017 Planned End Date changed from 28 Dec 2017 to 31 Dec 2017.
- 30 Oct 2017 Planned primary completion date changed from 28 Sep 2017 to 1 Dec 2017.
- 12 Jun 2017 New trial record